Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Embecta Corp (EMBC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $18.67
1 Year Target Price $18.67
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.15% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 586.18M USD | Price to earnings Ratio 11.27 | 1Y Target Price 18.67 |
Price to earnings Ratio 11.27 | 1Y Target Price 18.67 | ||
Volume (30-day avg) 5 | Beta 1.08 | 52 Weeks Range 9.20 - 20.80 | Updated Date 07/8/2025 |
52 Weeks Range 9.20 - 20.80 | Updated Date 07/8/2025 | ||
Dividends yield (FY) 6.20% | Basic EPS (TTM) 0.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.89% | Operating Margin (TTM) 30.35% |
Management Effectiveness
Return on Assets (TTM) 2.53% | Return on Equity (TTM) - |
Valuation
Trailing PE 11.27 | Forward PE - | Enterprise Value 1928378355 | Price to Sales(TTM) 0.54 |
Enterprise Value 1928378355 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA 9.32 | Shares Outstanding 58442500 | Shares Floating 57228657 |
Shares Outstanding 58442500 | Shares Floating 57228657 | ||
Percent Insiders 0.47 | Percent Institutions 101.37 |
Upturn AI SWOT
Embecta Corp
Company Overview
History and Background
Embecta Corp. was spun off from Becton, Dickinson and Company (BD) in April 2022. It focuses exclusively on diabetes care products, carrying forward BD's legacy in this sector. The company is relatively young as a standalone entity.
Core Business Areas
- Insulin Delivery: Embecta Corp. primarily focuses on insulin delivery devices, including pen needles and syringes used by people with diabetes to administer insulin.
Leadership and Structure
The leadership team consists of experienced executives with backgrounds in medical devices and pharmaceuticals. The organizational structure is designed to support its focus on diabetes care.
Top Products and Market Share
Key Offerings
- Pen Needles: Embecta offers a wide range of pen needles compatible with various insulin pens. Market share information is difficult to pinpoint exactly, but they are a major player globally in the pen needle market. Competitors include Novo Nordisk, B. Braun, and Owen Mumford.
- Syringes: Embecta manufactures insulin syringes. Market share information is difficult to pinpoint exactly, but they are a major player globally in the insulin syringe market. Competitors include B. Braun, and Nipro.
Market Dynamics
Industry Overview
The diabetes care market is driven by the increasing prevalence of diabetes globally. The industry is competitive, with companies offering various insulin delivery solutions and glucose monitoring systems.
Positioning
Embecta Corp. holds a strong position in the insulin delivery market, leveraging its history as part of BD. Its competitive advantages include its established brand, global distribution network, and focus on diabetes care.
Total Addressable Market (TAM)
The global diabetes care devices market is projected to reach hundreds of billions of dollars. Embecta is positioned to capture a portion of this market through its insulin delivery products.
Upturn SWOT Analysis
Strengths
- Established Brand
- Global Distribution Network
- Focus on Diabetes Care
- High-Volume Manufacturing Capabilities
- Strong customer relationships
Weaknesses
- Dependence on Insulin Delivery Market
- Relatively new standalone company
- Limited product diversification
- High debt levels
Opportunities
- Expanding into New Markets
- Developing Innovative Insulin Delivery Devices
- Acquiring Complementary Businesses
- Partnerships with Insulin Manufacturers
Threats
- Increased Competition
- Pricing Pressures
- Technological Advancements (e.g., insulin pumps, continuous glucose monitors)
- Changes in Healthcare Regulations
- Generic competition
Competitors and Market Share
Key Competitors
- NVO
- BDX
- MRK
Competitive Landscape
Embecta faces competition from established medical device companies and pharmaceutical giants. Its focus on insulin delivery gives it an advantage in this specific niche, but it needs to innovate to maintain its market position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to its recent spin-off. Provide Placeholder values here.
Future Projections: Detailed financial analysis requires real-time data. Provide Placeholder values here.
Recent Initiatives: Detailed financial analysis requires real-time data. Provide Placeholder values here.
Summary
Embecta Corp. is a relatively new company specializing in diabetes care, particularly insulin delivery systems. It benefits from a strong brand legacy and global presence. However, the company faces challenges including competition and needs to watch out for rapid technological advancements which could diminish its market share. Overall, Embecta has potential for growth but needs to strategically navigate a dynamic market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Verify information with independent sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Embecta Corp
Exchange NASDAQ | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2022-04-01 | President, CEO & Director Mr. Devdatt Kurdikar Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 2000 | Website https://www.embecta.com |
Full time employees 2000 | Website https://www.embecta.com | ||
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.